Description
Blend 500 is an oily injection solution with two long-acting anabolics: Trenbolone Enanthate and Masteron Enanthate. The typical split is 200mg Tren E plus 300mg Masteron E per ml for a total concentration of 500mg per ml.
Per study reports the blend combines two compounds with complementary pharmacology: Trenbolone as highly-potent 19-nor androgen without aromatization, Masteron as 2α-methylated DHT derivative with additional anti-estrogen action. Both compounds don’t aromatize; both yield dry muscle quality.
The two enanthate esters have synchronized half-lives (~7-10 days), enabling two weekly injections for stable plasma levels. The high volume per ml (500mg) reduces required injection amount.
In recreational research practice Blend 500 is used as long-running cutting or recomp stack, typically in 12-16 week cycles. A separate test base is mandatory because both Tren and Masteron suppress endogenous test production.
Known effects are the sum of both compounds: Tren-typical night sweats, sleep disturbances, aggression, prolactin elevation; Masteron-typical dry hardness and anti-estrogen action. Lipid profile worsens under both compounds; combined the worsening is relevant.
You can order Blend 500 as an oily injection solution in 10-pack at 500mg/ml.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Blend 500 combines two non-aromatizing anabolics - the risk profile described in the literature is the sum of Trenbolone Enanthate and Masteron Enanthate and sits in the sensitive range.
Documented in studies and the application literature:
- Trenbolone portion: as a highly-potent 19-nor compound with progestagenic residual action, elevated prolactin levels, night sweats, sleep disturbances and aggression are documented.
- Masteron portion: the 2-alpha-methylated DHT derivative does not aromatize, but mild androgenic effects such as acne and accelerated hair loss with predisposition are documented.
- Suppression of endogenous production: both Tren and Masteron suppress endogenous testosterone production via the HPTA axis, a separate test base is mandatory in research practice.
- Cardiovascular: both compounds worsen the lipid profile (HDL falls), and combined the deterioration described in the literature is relevant. Elevated hematocrit and thrombosis risk are documented.
Baseline bloodwork before, during and after a research protocol is strongly advised. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- 17β-Hydroxyestra-4,9,11-trien-3-one (trenbolone) exhibits tissue selective anabolic activity: effects on muscle, bone, adiposity, hemoglobin, and prostate - Am J Physiol Endocrinol Metab 2011, Yarrow et al: tissue-selective anabolic action of trenbolone on muscle, bone and fat.
- Improvements in body composition, cardiometabolic risk factors and insulin sensitivity with trenbolone in normogonadic rats - Steroids 2015, Donner et al: animal study on body composition, lipid profile and insulin sensitivity under trenbolone.
- Testosterone and trenbolone enanthate increase mature myostatin protein expression despite increasing skeletal muscle hypertrophy and satellite cell number in rodent muscle - Andrologia 2016, Dalbo et al: study of trenbolone enanthate, myostatin and satellite cells.
- A dose-response evaluation of androgens in the treatment of metastatic breast cancer - Cancer 1973, Talley et al: controlled study on dromostanolone (Masteron) in metastatic breast cancer.
- Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use - Circulation 2017, Baggish et al: cohort study on LV dysfunction and coronary atherosclerosis in chronic AAS users.
